Europe Pharmacogenomics Market By Technology (Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others), By Application (Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others), By End User (Hospitals and Clinics, Research Institutions, and Academic Institutes)

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Pharmacogenomics Market, by Application
1.4.2 Europe Pharmacogenomics Market, by Application
1.4.3 Europe Pharmacogenomics Market, by End User
1.4.4 Europe Pharmacogenomics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Pharmacogenomics Market by Technology
3.1.1 Europe Sequencing Market by Country
3.1.2 Europe Polymerase Chain Reaction Market by Country
3.1.3 Europe Electrophoresis Market by Country
3.1.4 Europe Mass Spectrometry Market by Country
3.1.5 Europe Microarray Market by Country
3.1.6 Europe Others Market by Country
Chapter 4. Europe Pharmacogenomics Market by Application
4.1.1 Europe Oncology Market by Country
4.1.2 Europe Psychiatry Market by Country
4.1.3 Europe Infectious Diseases Market by Country
4.1.4 Europe Neurological Diseases Market by Country
4.1.5 Europe Pain Management Market by Country
4.1.6 Europe Cardiovascular Diseases Market by Country
4.1.7 Europe Others Market by Country
Chapter 5. Europe Pharmacogenomics Market by End User
5.1.1 Europe Hospitals and Clinics Market by Country
5.1.2 Europe Research Institutions Market by Country
5.1.3 Europe Academic Institutes Market by Country
Chapter 6. Europe Pharmacogenomics Market by Country
6.1 Germany Pharmacogenomics Market
6.1.1 Germany Pharmacogenomics Market by Technology
6.1.2 Germany Pharmacogenomics Market by Application
6.1.3 Germany Pharmacogenomics Market by End User
6.2 UK Pharmacogenomics Market
6.2.1 UK Pharmacogenomics Market by Technology
6.2.2 UK Pharmacogenomics Market by Application
6.2.3 UK Pharmacogenomics Market by End User
6.3 France Pharmacogenomics Market
6.3.1 France Pharmacogenomics Market by Technology
6.3.2 France Pharmacogenomics Market by Application
6.3.3 France Pharmacogenomics Market by End User
6.4 Russia Pharmacogenomics Market
6.4.1 Russia Pharmacogenomics Market by Technology
6.4.2 Russia Pharmacogenomics Market by Application
6.4.3 Russia Pharmacogenomics Market by End User
6.5 Spain Pharmacogenomics Market
6.5.1 Spain Pharmacogenomics Market by Technology
6.5.2 Spain Pharmacogenomics Market by Application
6.5.3 Spain Pharmacogenomics Market by End User
6.6 Italy Pharmacogenomics Market
6.6.1 Italy Pharmacogenomics Market by Technology
6.6.2 Italy Pharmacogenomics Market by Application
6.6.3 Italy Pharmacogenomics Market by End User
6.7 Rest of Europe Pharmacogenomics Market
6.7.1 Rest of Europe Pharmacogenomics Market by Technology
6.7.2 Rest of Europe Pharmacogenomics Market by Application
6.7.3 Rest of Europe Pharmacogenomics Market by End User
Chapter 7. Company Profiles
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis